Endocrine Abstracts

Introduction: It is known that about 75% of cases of endogenous Cushing síndorme to a pituitary adenoma (HA) ACTH-producing, 15% to ectopic ACTH and 10% is due to adrenal adenoma.Case: The patient was 64 years old, derived from Diabetes Mellitus type 2 of about 16 years of history with an unwieldy+hypertension diagnosed in 2007 with no physical signs compatible with hypercortisolism and incidentally detected a left adrenal adenoma 2 cm. Hormonal blo...

Introduction: The prolactinoma is the most common functioning pituitary tumour. There are few long-term studies on the optimal duration of treatment with dopamine agonists prolactinoma to ensure healing without recurrence after stopping the medication and do not provide a consensus on it or on withdrawal criteria treatment.Objectives: To establish the prevalence of withdrawal of treatment macroprolactinomas and evaluate criteria prolactinoma cure medical...

Object: Nonfunctioning pituitary adenomas can experiment recurrence and/or progression (R/P) several years after surgery in about 15–50% of patients. There is few evidence about risk factors that could predict R/P. The aim of this study is to identify them and describe our experience through a long term of follow-up in pituitary macroadenomas.Methods: Retrospective cohort analysis of 64 patients who underwent surgery between 1990 and 2013. The main ...

Background: Up to 15% of pheochromocytomas are malignant. The only definite criterion for malignancy is the presence of metastases. The histological differentiation between benign and malignant tumours is difficult, being a challenging problem nowadays.Aim: To asses if postoperative histological evaluation using the previously proposed pheochromocytoma of the adrenal gland scales scored (PASS) can predict malignancy.Methods: Twenty...

Introduction: This study aimed to determine the timeframe to achieve hormonal normalization considering dosing patterns of Somatuline Autogel (SOM, lanreotide) used in clinical practice.Methods: From March 2013 to October 2013 clinical data from 62 patients with active acromegaly treated with SOM for &gE;4 months who achieved hormonal control (GH levels <2.5 ng/ml and/or normalised IGF1 on &gE;two evaluations) at 17 Spanish hospitals were collected i...